Biolife Solutions INC Form 4 insider transactions

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 10,000 shares of common stock on June 14, 2024, at a weighted average price of $20.18.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 408 shares of common stock on May 29, 2024, at a price of $21.78 per share.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 345 shares of common stock on May 29, 2024, to satisfy tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 517 shares of common stock on May 29, 2024, to satisfy tax withholding obligations.

Troy Wichterman, CFO of BioLife Solutions, sold 574 shares of common stock on May 29, 2024, at a price of $21.78 per share to cover tax withholding obligations.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 345 shares of common stock on May 29, 2024, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 73 shares of common stock on May 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 98 shares of common stock on May 17, 2024, to cover tax withholding obligations.

Troy Wichterman, CFO of BioLife Solutions, sold 115 shares of common stock on May 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 85 shares of common stock on May 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 57 shares of common stock on May 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions Inc., sold 10,000 shares of common stock on May 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Casdin Partners Master Fund, L.P. engaged in a cross-trade involving 150,000 shares of BioLife Solutions Inc. common stock at a price of $17.54 per share on April 30, 2024.

Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions, sold shares of common stock on April 18 and April 22, 2024, to cover tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions Inc., sold 481 shares of common stock on April 18, 2024, at a price of $15.31 per share to satisfy tax withholding obligations.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 584 shares of common stock on April 18, 2024, to cover tax withholding obligations.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 332 shares of common stock at $15.31 per share on April 18, 2024, to cover tax withholding obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 956 shares of common stock on April 18, 2024, to satisfy tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 10,000 shares of common stock at a price of $15.67 per share on April 15, 2024, under a pre-arranged trading plan.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 4,000 shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 454 shares of common stock on March 27, 2024, to cover tax withholding obligations.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 515 shares of common stock on March 27, 2024, to cover tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 395 shares of common stock on March 27, 2024, to cover tax withholding obligations related to vesting restricted stock.

BioLife Solutions CFO Troy Wichterman sold 520 shares of common stock on March 21, 2024, at a price of $17.83 per share to cover tax withholding obligations related to vesting restricted stock.

Director Amy DuRoss reports acquisition and disposal of BioLife Solutions (BLFS) common stock.

Garrie Richardson, Chief Revenue Officer of BioLife Solutions, reports acquiring 12,516 shares of common stock on March 8, 2024, as part of 2024 compensation.

Director Rachel Ellingson reports acquiring 11,264 shares of BioLife Solutions common stock on March 8, 2024.

Todd Berard, Chief Marketing Officer of BioLife Solutions, reports acquisition and disposal of company stock, including transactions made under a Rule 10b5-1 trading plan.

Director Joydeep Goswami reports acquisition of 11,264 shares of BioLife Solutions common stock on March 8, 2024.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, reports acquisition and disposal of common stock, including vesting of restricted stock and sales under a 10b5-1 trading plan.